吃瓜不打烊

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • 吃瓜不打烊 Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • The Body Shops
    • Priced Out
    • Guns, Race, and Profit
    • Broken Rehab
    • Dead Zone
    • Denied
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Sep 10 2021

Full Issue

What's Better Than A Covid Shot? How About One That Also Covers The Flu

Moderna said Thursday that it is developing a 2-in-1 booster jab that combines the covid and flu vaccines. In other news, BioNTech says it will file its paperwork on trial results for 5- to 11-year-olds "over the next few weeks."

Moderna announced Thursday that it is in the process of developing a new vaccine that combines a booster dose of its COVID-19 vaccine with a seasonal flu vaccine. "We believe this is just the beginning of a new age of information-based medicines," CEO St茅phane Bancel said in the press release, which also gave a slew of updates on projects the company is pursuing. (Saric, 9/9)

BioNTech is set to request approval across the globe for use of its COVID-19 vaccine in children as young as five over the next few weeks and preparations for a launch are well on track, two of the biotech firm's top executives told Der Spiegel. "Already over the next few weeks we will file the results of our trial in five to 11 year-olds with regulators across the world and will request approval of the vaccine in this age group, also here in Europe," Chief Medical Officer Oezlem Tuereci told the weekly magazine. (9/10)

The number of Latinos getting vaccinated against the coronavirus in some of the most populated cities in the U.S. is slowly increasing. Latinos have surpassed whites in the percentage of fully vaccinated adults in New York City. They represent 29.1% of the city's population and non-hispanic whites are 32.1%. (Gonzalez, 9/9)

Covid-19 vaccine boosters continue to stir controversy as most of the world seeks a first dose, not to mention the intense debate over the scientific evidence for their need and timing. Meanwhile, individuals are also grappling with ethical questions. We asked STAT readers if they had qualms about getting an extra dose before others had their first, and whether they thought their individual decisions mattered. (Cooney, 9/10)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, August 6
  • Wednesday, August 5
  • Tuesday, August 4
  • Monday, August 3
  • Friday, July 31
  • Thursday, July 30
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • 吃瓜不打烊
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 KFF